Literature DB >> 32816

[Spectrofluorimetric estimation in biological fluids of a new beta-blockader: atenolol. Application to its pharmacokinetic study (author's transl)].

B Flouvat, M Bazin, M Lucsko, A Roux, J Guedon.   

Abstract

The authors describe a simple method of fluorimetric estimation of atenolol, applicable to blood and urine, sufficiently sensitive to permit a pharmacokinetic study. After administration of a dose of 200 mg by the oral route to hypertensive subjects, one may observe a maximal plasma concentration 3 hours after the dose average value 3.91 +/- 0.71 mumol/l (1.04 +/- 0.19 mg/l). The apparent half life of elimination of phase beta is 14.1 +/- 4.9 h, values comparable with those calculated from urinary data 14.6 +/- 2.0 h. The renal clearance was 140 +/- 32 ml/min; 54 +/- 14% of the administered dose are excreted in the urine. After administration by the venous route, urinary excretion represents 96% of the dose administered.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 32816

Source DB:  PubMed          Journal:  Ann Biol Clin (Paris)        ISSN: 0003-3898            Impact factor:   0.459


  4 in total

1.  Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol.

Authors:  B Flouvat; A Roux; N P Chau; M Viallet; X Andre-Fouet; R Woehrle; J Gregoire
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

Review 2.  Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-06       Impact factor: 9.546

3.  Evolution of atenolol kinetics when hypothyroidism is corrected.

Authors:  H Levesque; M O Richard; J Fresel; A Gancel; N Moore; H Courtois
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.

Authors:  B Flouvat; S Decourt; P Aubert; L Potaux; M Domart; A Goupil; A Baglin
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.